Gilead Sciences Inc.’s Sovaldi (sofosbuvir) fared better than some expected in the FDA approval made public late in the day Friday, when the agency gave its blessing to 400-mg tablets of the once-daily nucleotide analog polymerase inhibitor for chronic hepatitis C virus (HCV) as part of a combination antiviral treatment regimen.